Astrazeneca Pharma India Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-06-2024
- Paid Up Capital ₹ 5.00 Cr
as on 23-06-2024
- Company Age 45 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 62.50 Cr
as on 23-06-2024
- Revenue 25.44%
(FY 2023)
- Profit 61.19%
(FY 2023)
- Ebitda 91.60%
(FY 2023)
- Net Worth 15.12%
(FY 2023)
- Total Assets 14.98%
(FY 2023)
About Astrazeneca Pharma India
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 506820 and on the National Stock Exchange(NSE) under ASTRAZEN.
The Corporate was formerly known as Astra Idl Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company has closed loans amounting to ₹62.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Astrazeneca Pharma India Limited India are Manasa Rama as COMPANY SECRETARY and Bhavana Agrawal as Cfo. Bhavana Agrawal, Hooi Chuah, Sanjeev Panchal, and Four other members serve as directors at the Company.
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Astrazeneca Pharma India?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Manasa Rama | Company Secretary | 11-Aug-2022 | Current |
Bhavana Agrawal | CFO | 01-Oct-2023 | Current |
Sanjeev Panchal | Managing Director | 01-Jan-2023 | Current |
Board Members(5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Shilpa Divekar | Director | 29-Dec-2021 | Current |
Revathy Ashok | Director | 02-Dec-2016 | Current |
Narayan Seshadri | Director | 06-Dec-2012 | Current |
Hooi Chuah | Director | Current | |
Ankush Nandra | Director | 18-May-2020 | Current |
Financial Performance and Corporate Structure Insights of Astrazeneca Pharma India.
Astrazeneca Pharma India Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.44% increase. The company also saw a substantial improvement in profitability, with a 61.19% increase in profit. The company's net worth Soared by an impressive increase of 15.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Astrazeneca Pharma India?
In 2023, Astrazeneca Pharma India had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Shell Mrpl Aviation Fuels And Services LimitedActive 16 years 9 months
Revathy Ashok is a mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
Il & Fs Trust Company Limited Creation Date: 16 Jan 2008 | ₹62.50 Cr | Satisfied |
How Many Employees Work at Astrazeneca Pharma India?
Astrazeneca Pharma India has a workforce of 935 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Astrazeneca Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astrazeneca Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.